AU2005259420A1 - Use of trisubstituted benzopyranones - Google Patents
Use of trisubstituted benzopyranones Download PDFInfo
- Publication number
- AU2005259420A1 AU2005259420A1 AU2005259420A AU2005259420A AU2005259420A1 AU 2005259420 A1 AU2005259420 A1 AU 2005259420A1 AU 2005259420 A AU2005259420 A AU 2005259420A AU 2005259420 A AU2005259420 A AU 2005259420A AU 2005259420 A1 AU2005259420 A1 AU 2005259420A1
- Authority
- AU
- Australia
- Prior art keywords
- plant extract
- general formula
- compounds
- compound
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/14—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 6 and unsubstituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004032440A DE102004032440B4 (de) | 2004-07-05 | 2004-07-05 | Verwendung von trisubstituierten Benzopyranonen |
DE102004032440.9 | 2004-07-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2005259420A1 true AU2005259420A1 (en) | 2006-01-12 |
Family
ID=35612964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2005259420A Abandoned AU2005259420A1 (en) | 2004-07-05 | 2005-06-30 | Use of trisubstituted benzopyranones |
Country Status (24)
Country | Link |
---|---|
US (1) | US20080020068A1 (fr) |
EP (1) | EP1763520B1 (fr) |
JP (1) | JP2008505064A (fr) |
KR (1) | KR20070038988A (fr) |
CN (1) | CN101044132A (fr) |
AR (1) | AR050908A1 (fr) |
AT (1) | ATE417842T1 (fr) |
AU (1) | AU2005259420A1 (fr) |
BR (1) | BRPI0513017A (fr) |
CA (1) | CA2570908A1 (fr) |
DE (3) | DE102004063910B4 (fr) |
DK (1) | DK1763520T3 (fr) |
ES (1) | ES2317258T3 (fr) |
GT (1) | GT200500182A (fr) |
MX (1) | MXPA06014844A (fr) |
PA (1) | PA8638301A1 (fr) |
PE (1) | PE20060528A1 (fr) |
PL (1) | PL1763520T3 (fr) |
PT (1) | PT1763520E (fr) |
RU (1) | RU2383537C2 (fr) |
TW (1) | TW200612903A (fr) |
UA (1) | UA88165C2 (fr) |
UY (1) | UY28976A1 (fr) |
WO (1) | WO2006002918A2 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1847236B (zh) * | 2006-05-16 | 2011-03-23 | 吉林省西点药业科技发展股份有限公司 | 7,8-二羟基-2-氧代-2h-苯并吡喃类衍生物及合成方法和医药用途 |
ATE471158T1 (de) | 2007-04-17 | 2010-07-15 | Schwabe Willmar Gmbh & Co | Verfahren zur herstellung von lagerstabilen lösungen aus pelargonium-extrakten |
AU2008238323B2 (en) * | 2007-04-17 | 2013-01-31 | Dr. Willmar Schwabe Gmbh & Co. Kg | Dry extracts of Pelargonium sidoides and Pelargonium reniforme |
US20100168225A1 (en) * | 2007-04-18 | 2010-07-01 | Francois Jean | Small-Molecule Hepatitis C Virus (HCV) NS3/4A Serine Protease Inhibitors |
KR100896453B1 (ko) * | 2007-07-18 | 2009-05-14 | 닥터 빌마르 쉬바베 게엠바하 운트 코 카게 | 페라고늄 시도이데스 시럽 |
CA2796070A1 (fr) * | 2010-04-16 | 2011-10-20 | Colby Pharmaceutical Company | Inhibiteurs du stress oxydatif induit par les androgenes |
TWI583677B (zh) * | 2012-09-21 | 2017-05-21 | 日本臟器製藥股份有限公司 | 香豆素衍生物 |
JP6089055B2 (ja) * | 2014-03-20 | 2017-03-01 | 日本臓器製薬株式会社 | クマリン誘導体を含有する医薬 |
CN106232116B (zh) * | 2014-03-20 | 2020-05-01 | 日本脏器制药株式会社 | 含有香豆素衍生物作为有效成分的治疗或预防剂 |
CN104974122B (zh) * | 2015-07-02 | 2017-03-22 | 云南中烟工业有限责任公司 | 一种源自烟草的香豆素化合物、其制备方法和用途 |
CN105461676B (zh) * | 2015-11-20 | 2017-12-12 | 上海秉丰生物科技有限公司 | 一种伪麻黄碱类衍生物及其制备方法与应用 |
WO2017213268A1 (fr) * | 2016-06-10 | 2017-12-14 | 国立大学法人東北大学 | Promoteur de la sécrétion d'insuline ou sensibilisateur à l'insuline. |
CN111803492B (zh) * | 2020-08-05 | 2022-03-29 | 苏州大学 | 一种香豆素类化合物在制备治疗乙肝药物中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4111861A1 (de) * | 1991-04-11 | 1992-10-15 | Schwabe Willmar Gmbh & Co | Benzopyranone, verfahren zu ihrer herstellung und verwendung |
DE4337906A1 (de) * | 1993-11-08 | 1995-05-11 | Cassella Ag | Verwendung von Cumarinderivaten |
EP1104672A1 (fr) * | 1999-12-02 | 2001-06-06 | Laboratoires Serobiologiques(Societe Anonyme) | Compositions cosmétiques et/ou pharmaceutiques |
US20030175777A1 (en) * | 2002-02-04 | 2003-09-18 | Bonagura Vincent R. | Eleutherosides as adjuncts for vaccines and immune modulation |
-
2004
- 2004-07-05 DE DE102004063910A patent/DE102004063910B4/de not_active Withdrawn - After Issue
- 2004-07-05 DE DE102004032440A patent/DE102004032440B4/de not_active Withdrawn - After Issue
-
2005
- 2005-06-09 TW TW094119109A patent/TW200612903A/zh unknown
- 2005-06-21 UY UY28976A patent/UY28976A1/es unknown
- 2005-06-30 AT AT05756337T patent/ATE417842T1/de active
- 2005-06-30 US US11/631,393 patent/US20080020068A1/en not_active Abandoned
- 2005-06-30 PL PL05756337T patent/PL1763520T3/pl unknown
- 2005-06-30 PT PT05756337T patent/PT1763520E/pt unknown
- 2005-06-30 CA CA002570908A patent/CA2570908A1/fr not_active Abandoned
- 2005-06-30 CN CNA2005800224393A patent/CN101044132A/zh active Pending
- 2005-06-30 KR KR1020067027823A patent/KR20070038988A/ko not_active Application Discontinuation
- 2005-06-30 ES ES05756337T patent/ES2317258T3/es active Active
- 2005-06-30 DK DK05756337T patent/DK1763520T3/da active
- 2005-06-30 JP JP2007518536A patent/JP2008505064A/ja not_active Withdrawn
- 2005-06-30 MX MXPA06014844A patent/MXPA06014844A/es active IP Right Grant
- 2005-06-30 RU RU2007104244/04A patent/RU2383537C2/ru not_active IP Right Cessation
- 2005-06-30 DE DE502005006286T patent/DE502005006286D1/de not_active Revoked
- 2005-06-30 WO PCT/EP2005/007051 patent/WO2006002918A2/fr active Application Filing
- 2005-06-30 UA UAA200612964A patent/UA88165C2/ru unknown
- 2005-06-30 AU AU2005259420A patent/AU2005259420A1/en not_active Abandoned
- 2005-06-30 EP EP05756337A patent/EP1763520B1/fr not_active Revoked
- 2005-06-30 BR BRPI0513017-4A patent/BRPI0513017A/pt not_active IP Right Cessation
- 2005-07-01 GT GT200500182A patent/GT200500182A/es unknown
- 2005-07-04 AR ARP050102782A patent/AR050908A1/es unknown
- 2005-07-04 PA PA20058638301A patent/PA8638301A1/es unknown
- 2005-07-05 PE PE2005000781A patent/PE20060528A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MXPA06014844A (es) | 2007-03-26 |
KR20070038988A (ko) | 2007-04-11 |
PL1763520T3 (pl) | 2009-06-30 |
DE102004063910B4 (de) | 2006-12-28 |
AR050908A1 (es) | 2006-12-06 |
DK1763520T3 (da) | 2009-02-09 |
PA8638301A1 (es) | 2006-03-24 |
US20080020068A1 (en) | 2008-01-24 |
GT200500182A (es) | 2006-03-17 |
WO2006002918A3 (fr) | 2006-05-04 |
UY28976A1 (es) | 2006-02-24 |
CN101044132A (zh) | 2007-09-26 |
JP2008505064A (ja) | 2008-02-21 |
RU2383537C2 (ru) | 2010-03-10 |
BRPI0513017A (pt) | 2008-04-22 |
CA2570908A1 (fr) | 2006-01-12 |
PE20060528A1 (es) | 2006-07-27 |
ATE417842T1 (de) | 2009-01-15 |
DE102004032440A1 (de) | 2006-02-16 |
RU2007104244A (ru) | 2008-08-10 |
ES2317258T3 (es) | 2009-04-16 |
WO2006002918A2 (fr) | 2006-01-12 |
EP1763520A2 (fr) | 2007-03-21 |
TW200612903A (en) | 2006-05-01 |
DE102004063910A1 (de) | 2006-02-09 |
DE102004032440B4 (de) | 2007-02-08 |
EP1763520B1 (fr) | 2008-12-17 |
UA88165C2 (en) | 2009-09-25 |
PT1763520E (pt) | 2009-03-23 |
DE502005006286D1 (de) | 2009-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005259420A1 (en) | Use of trisubstituted benzopyranones | |
Verotta | Are acylphloroglucinols lead structures for the treatment of degenerative diseases? | |
Shen et al. | Bioactive pyranoxanthones from the roots of Calophyllum blancoi | |
AU707798B2 (en) | Biflavanoids and derivatives thereof as antiviral agents | |
Shrestha et al. | Flavonoids from the fruits of Nepalese sumac (Rhus parviflora) attenuate glutamate-induced neurotoxicity in HT22 cells | |
Kupchan et al. | Macrocyclic spermidine alkaloids from Maytenus serrata and Tripterygium wilfordii | |
Hamed et al. | Flavonoidal glycosides and in vitro antioxidant activity of Bignonia binata Thunb. leaves Family Bignoniaceae and in silico evidence of their potential anti-COVID-19 activity | |
Rocha et al. | (3, 3 ″)-linked Biflavanones from Ouratea spectabilis and their effects on the release of Proinflammatory cytokines in THP-1 cells | |
Zeki et al. | 6, 7-Coumarin-Heterocyclic Hybrids: A Comprehensive Review of Their Natural Sources, Synthetic Approaches, and Bioactivity | |
EP0633887B1 (fr) | Composes antiviraux calanolides, compositions issues de ces composes et utilisations | |
AU6099194A (en) | Antiviral naphthoquinone compounds, compositions and uses thereof | |
Lim et al. | Antiplatelet activity of gallic acid and methyl gallate | |
Chen et al. | Flavonol dimers from callus cultures of Dysosma versipellis and their in vitro neuraminidase inhibitory activities | |
DK164865B (da) | Silibininderivater, fremgangsmaade til fremstilling deraf samt farmaceutisk middel indeholdende silibininderivaterne | |
KR101164020B1 (ko) | 손바닥선인장 추출물을 함유하는 약학 조성물 | |
JPH10287617A (ja) | 新規ジテルペン類及びジテルペン類を有効成分とする抗ウイルス剤 | |
KR100602683B1 (ko) | 아실-코에이:콜레스테롤 전이효소 저해활성을 갖는프탈레이트계 화합물 | |
Ospina et al. | Nitric oxide inhibitory activity of hydrogenated synthetic analogues of furanonaphthoquinones isolated from Tabebuia spp. | |
KR100933737B1 (ko) | 사자발쑥 추출물을 포함하는 약학 조성물 | |
KR20040046023A (ko) | 아실-코에이:콜레스테롤 전이효소 저해활성을 갖는테트라하이드로퓨란계 세스퀼리그난 화합물의 용도 | |
Anywar et al. | Bioactivity and toxicity of coumarins from African medicinal plants | |
KR20160010748A (ko) | 네팔 옻나무 유래의 플라보노이드 화합물들을 포함하는 신경 보호를 위한 조성물 | |
JPH07285877A (ja) | Hiv−1の逆転写酵素阻害剤 | |
KR100724088B1 (ko) | 플라보노이드계 화합물을 포함하는 심장순환계 질환의 예방및 치료용 조성물 | |
Copie et al. | Biflavanoids and derivatives thereof as antiviral agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |